BRCA-Associated Pancreatic Cancer: The Evolving Management
Abstract
Pancreatic cancer is one of the deadliest cancers. While BRCA-associated pancreatic cancers are uncommon, the distinctive phenotype of this malignancy may offer unique therapeutic targets. At the 2013 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, a review of the characteristics and outcomes of one large case series (Abstract #278), however, did not reveal a benefit to first-line platinum chemotherapy in the treatment of advanced pancreatic cancer. In another study (Abstract #147), substantial responses were observed in both patients with BRCA2-associated pancreatic cancer treated with the poly-(ADP-ribose) polymerase (PARP) inhibitor ABT-888 (veliparib). We will review these abstracts and our current knowledge of the treatment for patients with BRCA-associated pancreatic cancer. In this group of patients, these new results continue to shape our understanding of this disease.
Image: Tufts University School of Medicine. Boston, MA, USA.
Downloads
References
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians 2013; 63: 11–30. [PMID: 23335087].
Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 2011; 16:1397-1402. [PMID: 21934105]
Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog. 2012;51:14-24. [PMID: 22162228].
The Breast Cancer Linkage Consortium. Cancer Risks in BRCA2 Mutation Carriers. J Natl Cancer Inst 1999; 91(15): 1310-1316. [PMID: 10433620].
Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94:1358–65. [PMID: 12237281].
Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003; 97: 2187–2195. [PMID: 12712470].
Golan T, Kanji Z, Epelbaum R, Devaud N, Dagan E, Holter S et al. Chemosensitiviy and clinical characteristics of pancreatic malignancies in BRCA mutation carriers. J Clin Oncol 2013; Abstract 278.
Do K, Chen A. Molecular pathways: Targeting PARP in cancer treatment. Clin Cancer Res 2012; in publication. [PMID: 23269547].
Pishvaian M, Wang H, Zhuang T, He A, Hwang J, Hankin A, Ley L, et al. A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC). J Clin Oncol 2013; Abstract 147.
Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002; 62:3789–93. [PMID: 12097290].
Myriad Genetic Laboratories. “Panexia.” Www.Myriadpro.Com. Myriad Genetic Laboratories. Web Feb 2013. < https://www.myriadpro.com/test-offerings/genetic-testing/panexia>.
Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011; 306: 1557–1565. [PMID: 21990299].
Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, et al. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res 2011; 31(4): 1417-1420. [PMID: 21508395].
Copyright (c) 2014 Keith Leung, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.